🔗 Share this article

Given that the United States continues making historic changes to its vaccination schedules, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations during the global health crisis and has concentrated on potential deaths following Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Health officials planned to announce sweeping revisions to the childhood vaccination calendar in December, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would place the US at odds with many the international standard with no evidence for public health gain. The planned update has been postponed until the new year.

In place of Vinay Prasad, Høeg is set to address the audience at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth person to lead the office this year.

A Shift at the FDA

This interim role might represent a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for discontinuing certain childhood vaccine recommendations in the US so as to align more similar to Denmark's approach, a nation with universal health coverage and a number of inhabitants approximately the population of Wisconsin’s.

So far public appearances, she has kept her attention on immunizations – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Expertise

Høeg has no obvious experience in pharmaceutical research, approval processes or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a major agency. She is not an expert in pharmaceutical oversight.”

Former commissioners of the center would “grasp legal statutes and the science of drug development”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that previous people who ran the center have had.”

The drug center has an immense workload at the FDA, she pointed out.

“The public just pays attention on the innovative therapies, but the generic program clears numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and each of these have to be managed,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a major leadership element to the position, which oversees more than 5,000 personnel. “It is a huge management job, if you execute it properly,” Woodcock said.

Official Statement and Contentious Policies

Regarding inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “questions rely on incorrect premises”.

“This background matches the duties of her job,” the spokesperson said, noting the period Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed one-day medication authorization process that reportedly troubled her former heads. “By what process are these drugs being chosen for this voucher program? Who is making the calls?” Dr. Howard asked. “There’s a lot of secrecy going on at the agency right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer oversight of pharmaceuticals, except for shots.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more documented, if concerning, history, some experts said. She authored a research paper using unverified crowd-sourced reports to assess the rate of myocarditis after COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are more dangerous than they are.

Among her “desired changes” for the incoming administration encompassed altering rules for novel immunizations and halting “optional” immunizations, she said post-election on a online show. At the FDA, Høeg has reportedly floated the idea of excluding young men from getting Covid vaccines.

“She’s an thorough ideologue who commences with her conclusions and works backwards to retrofit the science in a extremely misleading, fraudulent way,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|